Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
about
Current perspectives on HIV-1 antiretroviral drug resistanceProtease-resistant peptide design-empowering nature's fragile warriors against HIVDesign of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to ResistanceImpact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolatesClosing the door to human immunodeficiency virus.Bayesian bent-cable growth mixture tobit models for longitudinal data with skewness and detection limit: application to AIDS studies.HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry.Multivalent antiviral XTEN-peptide conjugates with long in vivo half-life and enhanced solubilityR5X4 HIV-1 coreceptor use in primary target cells: implications for coreceptor entry blocking strategies.Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 PocketVicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer.Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma virusesHIV-1 drug-resistance and drug-dependence.Non-natural peptide triazole antagonists of HIV-1 envelope gp120.The remarkable frequency of human immunodeficiency virus type 1 genetic recombinationHIV-1 Entry, Inhibitors, and ResistanceEscape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment.Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 functionComplex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors.Bayesian analysis of piecewise growth mixture models with skew-t distributions: Application to AIDS studies.Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket.Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide.A spatially varying two-sample recombinant coalescent, with applications to HIV escape response.Enfuvirtide antiretroviral therapy in HIV-1 infection.Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100.Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry.Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile.
P2860
Q26852626-5B5159B7-939C-4B16-8020-737369B54761Q27010058-DF9825A3-922B-4B03-BAB3-CFEDCE09AD27Q27664086-7C68A80C-EA32-406B-9C16-B665733B0950Q28478943-35140A62-E880-4019-92E1-BD30820A7F9BQ30428089-7416AB3D-5005-4C22-A820-F265C85EE5D2Q31120461-F28B34E2-F8D7-417D-856C-C27DA79477DCQ33807529-26E69848-B726-4D9A-B78C-73D2F95E99FBQ33857491-AB0D45F4-78F1-4198-99E4-65BD1D58F1A1Q34149681-BC462492-4412-4E43-9F30-44FFB81ECBF0Q35018129-E7A5C999-9057-4B8F-93B7-453FBDB61740Q35641194-52E8675E-C911-4C42-A6FE-5F271422310DQ36086642-0230C107-7874-420B-9D42-34E7C7C86963Q36228646-70229138-BF8A-46CA-AC70-A15BE15C9F49Q36334376-E4A919F2-A2F0-4943-AB45-7E5D9D315FE6Q36502557-D3BEA6EA-A1F5-492D-B984-3EA2CA61CCBDQ36981758-6050B355-EF39-4E43-8DA7-8C3044BBC1C9Q37260033-482A6F93-8425-4ADB-AF73-780DD550D0C2Q37333701-56EBF324-698C-41A1-AF81-E162B4875BE4Q37945205-D105FE81-432C-4F57-B3AE-35116E6B1D19Q38076139-69289921-590A-4691-B1B2-7CFB2BFBCD7EQ38196457-ED830ED6-7206-4946-9967-7473F776EB33Q38423190-003ED6B3-7329-43A1-9372-75CF59362C2AQ38632078-574C8B09-496A-48F0-A6DC-831663ECC5FFQ38684463-7C597388-465B-459D-9C4F-991F57CD18E9Q39068397-3F7D952E-7C90-4DDE-BF1E-D53933AC8765Q39455561-7F555551-C0BE-4DEA-B486-DB98E1157845Q39843204-8BE762D3-DCB9-4AD1-B8DD-C659B924FB51Q39893554-3E21C093-9951-42F9-9F23-1C16B764BB8EQ40906876-BE4289C4-9F06-4681-9D51-47F333586FEEQ41715047-405053F4-B7BB-4522-85EF-41C885408BCAQ41760939-EBBF98E3-4AA6-4C09-AB57-2D22380A82BFQ41857872-FAAFE2AF-D030-4B73-A7D7-308940283A5EQ42321693-15FA05ED-C66C-4169-AB7E-1097F695A49DQ47383689-BC6D0715-B7E8-4F51-BE4C-95152F9FA1E8
P2860
Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Clinical resistance to enfuvir ...... r classes of entry inhibitors.
@en
type
label
Clinical resistance to enfuvir ...... r classes of entry inhibitors.
@en
prefLabel
Clinical resistance to enfuvir ...... r classes of entry inhibitors.
@en
P2093
P2860
P356
P1433
P1476
Clinical resistance to enfuvir ...... r classes of entry inhibitors.
@en
P2093
Jeffrey N Martin
Jessamina E Harrison
Leslie A Blackburn
Neelanjana Ray
Robert W Doms
P2860
P304
P356
10.1128/JVI.02413-06
P407
P577
2007-01-24T00:00:00Z